Skip to main content

Table 1 Baseline characteristics and treatment patterns of all patients

From: Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified

Characteristics MBC IDC-NOS P value
  n = 188 n = 2,202  
  n % n %  
Age (years)      
≤40 31 16.5. 290 13.2 0.200
>40 157 83.5 1,912 86.8  
Tumor size      
T ≤2 82 43.4 623 28.3 <0.001
2< T ≤5 102 54.0 1,277 58.0  
T >5 5 2.6 170 7.7  
Unknown 0 0 132 6.0  
Nodal status      
0 132 70.2 1,130 51.3 <0.001
1 to 3 45 23.9 559 25.4  
4 to 10 8 4.3 347 15.8  
>10 3 1.6 110 5.0  
Unknown 0 0 56 2.5  
TNM stage      
I 61 32.4 433 19.7 <0.001
II 117 62.2 1,537 69.8  
IIA 102 54.3 1,253 56.9  
IIB 15 8.0 284 12.9  
III 10 5.3 215 9.8  
Unknown 0 0 17 0.8  
ER status      
Negative 111 59.0 1,167 53.0 0.005
Positive 62 33.0 1,028 46.7  
Unknown 15 8.0 7 0.3  
PR status      
Negative 82 38.0 1,100 50.0 0.005
Positive 119 55.1 1,053 47.8  
Unknown 15 6.9 49 2.2  
HR status      
Negative 94 50.0 785 35.6 <0.001
Positive 79 42.0 1,395 63.4  
Unknown 15 8.0 22 1.0  
HER2/neu status      
Negative 142 68.3 1,512 68.7 0.003
Positive 27 13.0 546 24.8  
Unknown 39 18.8 144 6.5  
Triple-negative      
Yes 76 40.4 550 26.2 <0.001
No 107 56.9 1,610 71.8  
Unknown 5 2.7 42 2.0  
Surgery      
Mastectomy 181 96.3 2,122 96.4 0.949
BCS 7 3.7 80 3.6  
Chemotherapy      
Undo 28 14.9 230 10.4 <0.001
Methotrexate included 73 38.8 857 38.9  
Anthracyclin included 74 39.4 980 44.5  
Taxane included 12 6.4 30 1.4  
Others 1 0.5 10 0.5  
Unknown 0 0 95 4.3  
Radiotherapy      
Undo 168 89.4 1,718 78.0 0.002
Do 18 9.6 402 18.3  
Unknown 2 1.1 82 3.7  
Hormonotherapy      
Undo 125 66.5 1,216 55.2 0.002
Do 60 31.9 961 43.6  
Unknown 3 1.6 25 1.1  
p53      
Negative 52 27.7 214 29.7 0.018
Positive 110 58.5 700 31.8  
Unknown 26 13.8 848 38.5  
Cathepsin-D      
Negative 59 31.4 366 16.6 0.001
Positive 94 50.0 1,022 46.4  
Unknown 35 18.6 814 37.0  
PCNA      
Negative 67 36.4 1,270 57.7 <0.001
Positive 87 47.3 484 22.0  
Unknown 30 16.3 448 20.3  
  1. BCS, breasting-conserving surgery; ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; HR, hormone receptor; IDC-NOS, infiltrating ductal carcinoma-not otherwise specified; MBC, medullary breast carcinoma; PCNA, proliferating cell nuclear antigen; PR, progesterone receptor.